

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

HIGHLY SELECTIVE MAT2A INHIBITOR (SYH2039) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that a highly selective MAT2A inhibitor (SYH2039) (the “**Product**”), a new Class 1 chemical drug developed by the Group, has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S. Prior to this, the Product already obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China in March 2024.

SYH2039 is a highly active methionine adenosyltransferase 2A (MAT2A) inhibitor that can selectively kill MTAP-deficient tumor cells while having minimal impact on normal cells. The Product can be used alone or in combination with second-generation PRMT5 inhibitors to achieve synergistically enhancing efficacy. The indication for this clinical trial approval is advanced malignant tumors. Preclinical studies have demonstrated that the Product can effectively inhibit the growth of various MTAP-deficient tumor cells such as non-small cell lung cancer, glioma, gastroesophageal cancer, pancreatic cancer and bladder cancer, with remarkable in-vivo and in-vitro activity. The Product also has good pharmacokinetics (PK) properties as well as a good safety profile, potentially to become a best-in-class anti-tumor drug. Multiple patent applications have currently been filed in China and overseas. Huge clinical needs exist as MTAP-deficient tumors lack effective targeted therapies, thus providing a promising clinical development value.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 26 April 2024

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.